The Paris Bourse fell 0.51% in mid-session Monday, subject as the previous week to fears of a rise in inflation and a monetary tightening of central banks if the health and economic situation were to normalize .
The CAC 40 index fell 29.36 points to 5,744.19 points around 12:20 p.m., after a checkered week resulting in a weekly increase of 1.23%.
"The current growing fears over the acceleration of inflation continue to encourage investors to take part of the profits on equities", comments Pierre Veyret, analyst for ActivTrades.
In addition, expectations of higher inflation and economic recovery are reflected in interest rate hikes in the bond market.
However, this rise can lead to arbitrage between the purchase of stocks or bonds, the latter becoming more and more interesting.
The French ten-year rate surpassed Monday a highest since June 2020, at -0.05%.
Rates on the bond market are being pushed up by the United States, where expansionary fiscal policy suggests a sharp rise in prices.
Inflation there settled at 1.3% in 2020, and should hover around 2.25% in 2022, "which is nothing to worry about", however noted Friday Gita Gopinath, chief economist of the International Monetary Fund (IMF).
It considers it "unlikely" that inflation will settle permanently above the target of 2% per year.
Sanofi to produce Johnson & Johnson vaccines
Sanofi (-0.27% to 76.80 euros) announced Monday that it was launching a new so-called "phase 2" clinical trial for its main candidate vaccine against Covid-19 developed with the British GSK, hoping to put it available in the fourth quarter.
The laboratory has also announced that it will produce in France the vaccine against the Covid-19 of its American competitor Johnson & Johnson in the second half of the year, as it is also preparing to do for the one developed by Pfizer / BioNTech.
Valneva: phase 3 for a vaccine
The Franco-Austrian biotech (-1.63% to 12.08 euros), which works in particular on the Covid-19, announced Monday the launch of a study on the homogeneity of clinical batches of "phase 3" of its Single injection vaccine candidate against chikungunya.
Faurecia bounces back
The sales of the equipment manufacturer Faurecia (-3.45% to 45.04 euros) rebounded strongly in the second half of 2020, allowing it to limit losses to 379 million euros over the year.
© 2021 AFP